UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has recruited Annette Møldrup as Chief Business Development Officer and Kia Bengtsson as Head of Clinical Development. Both have extensive experience from the pharmaceutical industry and will assume their new roles in the autumn 2022.
“This is an important step for LIDDS’ future development and I am very happy to welcome Annette and Kia to the company. With Annette’s business development experience we will take an important step towards increasing our ability to negotiate and realize deals and also improve the awareness about LIDDS internationally. Through Kia we will get strong contribution to the clinical development of our portfolio.” says Nina Herne, CEO of LIDDS.
Annette Møldrup has long experience from the pharmaceutical industry where she has worked within global business development at Novo Nordisk and most recently at Ferring. Annette will be part of the management team. She has a Cand.Scient of Biochemistry and PhD of Molecular and Cellular Biology from University of Copenhagen. Annette assumes her new role on September 1, 2022.
Kia has 25 years experience from clinical development from among others AstraZeneca, Nanologica, Eurocine Vaccines and Ipsen. She comes most recently from the role as Head of Clinical Development at Vivesto. Kia is a registered nurse from the Karolinska Institute and assumes her new role on October 1, 2022